Few thoughts looking at the extra date:
-I wonder why the PR (nearly 40% reduction) is off the trial?
-Also what do people make of the viral Spect comments, some in the effective treatment group don’t have any number next to them and plenty of time for a scan on the trial. The omission makes it seem like there wasn’t any detected, but that seems unlikely - unless reliability of measuring tumour is less than I would have guessed (therefore allowing for reductions within SD range, but actually just being measurement error).
9 comments on the viral scan, with 6 above the line and only 3 below which isn’t in line with what I’d expect.
-We had one so close to a PR in October!
Ann: Imugene Presentation to JPMorgan Healthcare Conference, page-36
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.4¢ | $417.0K | 9.281M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 6074903 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 362283 | 5 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |